Market Overview

The Global Atopic Dermatitis Drugs Market was valued at USD 16,493.1 million in 2023 and is expected to reach USD 33,105.5 million by 2031 while growing at a CAGR of 9.1% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global atopic dermatitis drugs market growth. Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin, for which drugs are used to manage both the symptoms and underlying inflammation.

The rising prevalence of atopic dermatitis and ongoing research and development efforts lead to the introduction of novel drugs and therapies, propelling the atopic dermatitis (AD) drugs market. Nevertheless, side effects, safety concerns, and the high cost of treatment impede market growth.

Furthermore, the global atopic dermatitis drugs industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Drug Class Analysis

The Global Atopic Dermatitis Drugs Market is segmented among Corticosteroids, Emollients/Moisturizers, IL-4 and PDE4 Inhibitors, Calcineurin Inhibitors, Antibiotics, and Other Drug Classes, based on Drug Class. In 2023, Corticosteroids accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Segmentation – By Route of Administration Analysis

The Global Atopic Dermatitis Drugs Market is segmented among Topical, Oral, and Injectable, based on Route of Administration. In 2023, Injectable accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Atopic Dermatitis Drugs Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Pfizer Inc., Sanofi, AbbVie Inc., Galderma Laboratories L.P, Eli Lily and Company, Regeneron Pharmaceuticals Inc., LEO Pharma Inc., Otsuka Pharmaceuticals Co. Ltd, Novartis AG, and Incyte Corporation

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Atopic Dermatitis Drugs Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Atopic Dermatitis Drugs Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Atopic Dermatitis Drugs Market Segmentation, By Drug Class

• Global Atopic Dermatitis Drugs Market Share Analysis, By Drug Class

• Global Atopic Dermatitis Drugs Market Growth Analysis, By Drug Class

• Global Atopic Dermatitis Drugs Market Trends, By Drug Class

o Corticosteroids

o Emollients/Moisturizers

o IL-4 and PDE4 Inhibitors

o Calcineurin Inhibitors

o Antibiotics

o Other Drug Classes

6. Global Atopic Dermatitis Drugs Market Segmentation, By Route of Administration

• Global Atopic Dermatitis Drugs Market Share Analysis, By Route of Administration

• Global Atopic Dermatitis Drugs Market Growth Analysis, By Route of Administration

• Global Atopic Dermatitis Drugs Market Trends, By Route of Administration

o Topical

o Oral

o Injectable

7. Global Atopic Dermatitis Drugs Market Segmentation, By Region

• Global Atopic Dermatitis Drugs Market Share Analysis, By Region

• Global Atopic Dermatitis Drugs Market Growth Analysis, By Region

• Global Atopic Dermatitis Drugs Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

8. Competitive Landscape

• Pfizer Inc.*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Sanofi

• AbbVie Inc.

• Galderma Laboratories L.P

• Eli Lily and Company

• Regeneron Pharmaceuticals Inc.

• LEO Pharma Inc.

• Otsuka Pharmaceuticals Co. Ltd

• Novartis AG

• Incyte Corporation

*Similar analysis will be provided for each company listed above.